Black Diamond Therapeutics, Inc. (BDTX)

5.89 +0.78 (+15.26%) At close: 04:00PM EDT

Black Diamond Therapeutics, Inc.

One Main Street
14th Floor
Cambridge, MA 02142
United States
617 252 0848
https://www.blackdiamondtherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 54

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mark A. Velleca M.D., Ph.D.	CEO, President & Chairman	795.98k	N/A	1964
Dr. David M. Epstein Ph.D.	Co-Founder & Director	969.69k	N/A	1959
Dr. Fang Ni Pharm.D.	CFO, Principal Financial Officer and Chief Business Officer	665.98k	N/A	1987
Dr. Sergey Yurasov M.D., Ph.D.	Chief Medical Officer	718.92k	N/A	1969
Dr. Elizabeth Buck Ph.D.	Co-Founder & Chief Scientific Officer	340.47k	N/A	1975
Mr. Brent Hatzis-Schoch Esq., J.D.	COO & General Counsel	683.29k	N/A	1965
Ms. Elizabeth L. Montgomery	Chief People Officer	N/A	N/A	1972
Ms. Melanie Morrison	Chief Development Officer	N/A	N/A	1975
Ms. Erika Jones	Senior VP of Finance & Corporate Controller	N/A	N/A	1985

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Black Diamond Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.